Glucagonoma
Information
- Disease name
- Glucagonoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01824875 | Active, not recruiting | Phase 2 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | August 8, 2013 | December 2024 |
| NCT00075439 | Completed | Phase 2 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | December 2003 | |
| NCT00131911 | Completed | Phase 2 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | June 2005 | April 2013 |
| NCT00655655 | Completed | Phase 1 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | December 2004 | January 11, 2018 |
| NCT01525082 | Completed | Phase 2 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | December 2012 | December 31, 2019 |
| NCT00004074 | Completed | Phase 1 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | August 1999 | |
| NCT02259725 | Completed | Phase 2 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | August 16, 2016 | August 20, 2020 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT02031536 | Terminated | Phase 2 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | April 10, 2014 | July 19, 2017 |
| NCT02273752 | Terminated | Phase 2 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | November 2014 | December 2015 |
| NCT00084461 | Terminated | Phase 2 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | March 2004 | |
| NCT02108782 | Withdrawn | Phase 2 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | October 2014 | May 2015 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030404
- OrphaNumber from OrphaNet (Orphanet)
- 97280
- MeSH unique ID (MeSH (Medical Subject Headings))
- D005935